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Personalized cancer vaccines hold promises for future cancer therapy. Targeting
neoantigens is perceived as more beneficial compared to germline, non-mutated
antigens. However, it is a practical challenge to identify and vaccinate patients with
neoantigens. Here we asked whether two neoantigens are sufficient, and whether the
addition of germline antigens would enhance the therapeutic efficacy. We developed
and used a personalized cancer nano-vaccine platform based on virus-like particles
loaded with toll-like receptor ligands. We generated three sets of multi-target vaccines
(MTV) to immunize against the aggressive B16F10 murine melanoma: one set based
on germline epitopes (GL-MTV) identified by immunopeptidomics, another set based
on mutated epitopes (Mutated-MTV) predicted by whole exome sequencing and a last
set combines both germline and mutated epitopes (Mix-MTV). Our results demonstrate
that both germline and mutated epitopes induced protection but the best therapeutic
effect was achieved with the combination of both. Our platform is based on Cu-free
click chemistry used for peptide-VLP coupling, thus enabling bedside production of a
personalized cancer vaccine, ready for clinical translation.
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INTRODUCTION
Melanoma is the most aggressive type of skin cancer mostly due to its highmetastatic potentials (1).
The complexity of melanoma phenotype affects its responsiveness to various therapies. Therefore,
scientists emphasize the need for personalized treatments, including vaccinations that target
neoantigens representing the uniqueness of each patient’s tumor (2, 3). Neoantigens are considered
attractive because T-cells specific for these altered-self antigens are not expected to be attenuated by
immune tolerance mechanisms as compared to T-cells specific for conserved self-antigens (4–6).
Given the facts that powerful tumor infiltrating T-cells recognize multiple tumor antigens (7),
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and that targeting of a single antigen allows tumors to relapse
(8), it is desirable to target multiple antigens (3, 9, 10). However,
identifying sufficient numbers of neoantigens may be difficult for
many human tumors that often show low mutational burden
such as prostate and pancreatic cancers (11–13). Targeting
neoantigens by using synthetic long peptides (14), RNA-based
vaccines (15), or DC-based vaccines (16) have so far only
been done in patients with tumors of high mutational burden,
essentially melanoma.
We have shown previously that VLPs derived from the
bacteriophage Qβ loaded with A-type CpGs and coupled to
MelanA/MART-1 peptide can be efficiently processed by murine
and human DCs for MHC-I presentation and induced strong
CD8+ T-cell responses in HLA-A2 transgenic mice as well as in
melanoma patients (17, 18). Recent research has also shown that
CMP-001, a product that is also based on Qβ-VLPs loaded with
the same A-type CpGs induced tumor regressions in advanced
melanoma patients treated by direct intra-tumoral injection,
even though the VLPs used were not linked to tumor-specific
antigens. Three clinical trials for CMP-001 are currently ongoing
(NCT02680184, NCT03084640, and NCT03618641).
In this study, we have utilized VLPs to build up a personalized
multi-target vaccine based on identified germline and predicted
mutated peptides coupled to TLR 9-ligand loaded VLPs by the
non-toxic bio-orthogonal Cu-free click chemistry. The generated
vaccine candidates induced effective CD8+ T-cell responses and
the strategy can also be implemented for solid tumors with low
mutational burdens as identification of germline epitopes with
high affinity to MHC-I molecules is always feasible.
MATERIALS AND METHODS
Production and Purification of Qβ-VLPs
Qβ-VLPs expression and production was performed as
previously described in detail in Kozlovska et al. (19), Cielens
et al. (20), and Storni et al. (21).
Packaging Qβ-VLPs With B-Type CpGs
B-type CpGs (5′′-TCC ATG ACG TTC CTG ATG CT-3′′) with
phosphorothioate backbone was customemade by (IBA). Twenty
mMHEPES (Sigma Aldrich) was used to solubilize Qβ-VLPs and
RNase A (Merck) was used to digest the naturally packaged RNA
inside Qβ-VLPs (1.2 mg/ml RNaseA/ 3 mg/ml Qβ-VLPs) for 3 h
at 37◦C. The digestion was confirmed using 1% agarose gel and
SYBR safe dye. Qβ-VLPs was then repackaged with B-type CpGs
(1.125µg/ 20µg Qβ-VLPs) and packaging was also confirmed by
using 1% agarose gel stained by SYBRsafe stain, while Qβ-VLPs
protein was detected by subsequent staining with coomassie blue.
Generation of Qβ(CpGs)-p33 Vaccine Using
SMPH Chemistry
B-type CpGs were packaged in Qβ-VLPs as described earlier
and then derivatized for 1 h at RT using SMPH (Succinimidyl
6-((beta-maleimidopropionamido)hexanoate)) (Thermo
Fisher Scientific). Excess SMPH cross-linker was removed
using Amicon centrifuge tubes of 100 kDa MWCO (Sigma-
Aldrich). Modified p33 peptide—derived from Lymphocytic
Choriomeningitis Virus LCMV—was synthesized by the
addition of GGC amino acids (a.a.) at the C-terminus “H-
KAVYNFATMGGC-NH2” (Pepscan BRESTO) to facilitate its
coupling to SMPH cross-linker. The modified peptide was
reconstituted in DMSO and added in 10-fold molar excess over
Qβ(CpGs)-VLPs monomer. The mixture was incubated for 1 h
at RT and excess peptide was removed using Amicon centrifuge
tubes. The coupling efficiency was tested by SDS-PAGE stained
with coomassie blue and assessed by densitometric analysis
of the SDS-PAGE by comparing Qβ-VLP monomer bands to
Qβ-VLP monomer plus p33 after coupling.
Generation of Qβ(CpGs)-p33 Vaccine and
Multi-Target Vaccines Using DBCO
(Cu-Free Click Chemistry)
B-type CpGs were packaged in Qβ-VLPs as described
earlier and then derivatized for 30min at RT using DBCO
(dibenzocyclooctyne NHS ester) (Sigma-Aldrich). Excess DBCO
cross-linker was removed using Amicon centrifuge tubes of
100 kDa MWCO (Sigma-Aldrich). Modified p33 peptide was
synthesized by the addition of GGCK a.a. and an azide (N3)
group at the C-terminus “H-KAVYNFATMGGCK(N3)-NH2”
(Pepscan BRESTO) to facilitate its coupling to DBCO cross-
linker. The peptides for the multi-target vaccines (MTV) were
synthesized by the addition of extra 4 a.a. using their flanking
protein sequence and an azide (N3) group at the C-terminus.
The generation of multi-target vaccine was done for each
peptide separately. The modified peptides were reconstituted in
DMSO and added in 10-fold molar excess over Qβ(CpGs)-VLPs
monomer. The vaccine was incubated for 30min at RT and
excess peptide was removed using Amicon centrifuge tubes.
The efficiency of the coupling was tested as explained in section
Generation of Qβ(CpGs)-p33 vaccine using SMPH chemistry.
Mice
Wild type C57BL/6 mice were purchased from Harlan. Rag2−/−
mice on a C57BL/6 background were provided by Ochsenbein’
lab and bred in our pathogen-free animal facility. All in vivo
experiments used 8–12-week-old female. All animal procedures
were performed in accordance with the Swiss Animals Act
(455.109.1) (September 2008, 5th) of University of Bern.
Measuring p33 Specific T-Cell Response
With Tetramers
P33 (H-KAVYNFATM-NH2) tetramers designed with H2-Db
allele and APC or PE fluorochrome (TCMetrix) was used to
measure p33 specific T-cells. WT C57BL/6 mice (8–12 weeks
old; Harlan) were vaccinated s.c. once with 50 µg Qβ(CpGs)-
p33 vaccine coupled with SMPH or DBCO cross-linkers. Seven
days later spleens were collected and smashed using 70µM
cell strainer (Sigma-Aldrich). Cells were washed 1x with sterile
PBS and RBCs were lysed using ACK lysis buffer. ∼1 × 106
cells were collected in 96-well V-bottom plate and stained with
p33 tetramers (TCMetrix) followed by anti-CD8α (53–6.7, BD
Biosciences) for flow cytometric analysis by FACSCanto and
FlowJo Software.
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Intra-cellular Cytokine Staining for IFN-γ
Intra-cellular cytokine staining was performed on spleens or
TILs of vaccinated mice to measure IFN-γ. ∼2 × 106 cells were
collected from spleen or TIL and pulsed with 1 µg of p33 peptide
or with the mixture of germline peptides or mutated peptides or
both according to the vaccine group for 6 h at 37◦C with 1:1,000
Brefeldin A andMonensin (BD Biosciences). Cells were collected
and washed 3x with sterile PBS/0.1% BSA. ∼1 × 106 cells were
collected in 96-well V-bottom plate and stained with anti-CD8α
(53–6.7, BD Biosciences). Cells were then fixed with 100 µl of
the fixation buffer (Thermo Fisher Scientific) and permeabilized
with 1x of the permeabilization buffer (Thermo Fisher Scientific).
Cells were stained with anti-IFN-γ (XMG1.2, BD Biosciences) for
flow cytometric analysis by FACSCanto and FlowJo Software.
CFSE in vivo Cytotoxic Assay
WT C57BL/6 mice (8–12 weeks old; Harlan) were vaccinated
with a single s.c. injection of 50 µg Qβ(CpGs)-p33 vaccine
coupled with SMPH cross-linker or DBCO cross-linker. Seven
days later, target splenocytes from naïve WT C57BL/6 mice
were collected and RBCs were lysed and divided into 2 groups.
The 1st naïve splenocyte group was labeled with 2µM CFSE
(Thermo Fisher Scientific) and kept un-pulsed while the 2nd
naïve splenocytes group was first pulsed with 1 µg p33 and
then labeled with 10µM CFSE. The prepared target groups were
mixed in 1:1 ratio and each previously vaccinated mouse received
1 × 107 of un-pulsed CFSELow cells and 1 × 107 of pulsed
CFSEHi cells intravenously. Four hours later the spleens of the
vaccinated mice were collected and analyzed by flow cytometry
for frequency of CFSELow and CFSEHi. Specific lysis for each
group was measured using the formula “Ratio= 100X(1–CFSEHi
pulsed/CSFELow un-pulsed).”
Immunopeptidomics
B16F10 melanoma cell line transfected with p33 peptide was
provided by Ochsenbein’s lab and cultured in T-150 cm2
flask using Dulbecco’s modified Eagle’s medium (DMEM) with
10%FBS and 1% Streptomycin/Penicillin. Cells at 80% confluency
were washed 2x with sterile PBS and collected with scrapers,
centrifuged and freezed at −80◦C. Cells were lysed using 5ml
lysis buffer (1% Igepal, 300mM sodium chloride, 100mM Tris,
pH 8.0) supplemented with protease inhibitor cocktail (Roche)
for 30min on ice. Lysates were cleared by two centrifugation
steps at 500 g for 10min and then 20,000 g for 60min. One
mg of anti-mouse MHC class I antibody (ATCC HB-51) was
bound and cross-linked to 1ml Protein G beads (GE healthcare).
Lysates were incubated with the antibody beads over night at 4◦C
and washed subsequently with 50mM Tris, pH 8.0 containing
either 150, 450mM, and no salt. Peptides were eluted with 5ml
10% acetic acid and concentrated in a vacuum concentrator
(Eppendorf). Peptides were then injected onto a 4.6 × 50mm
ProSwift RP-1S column on an Ultimate 3000 system (Thermo
Fisher Scientific). Peptides were separated from larger complex
components by elution using a 500 µl/ min flow rate over
10min from 2 to 30% ACN in 0.1% TFA. Alternate fractions
that did not contain the beta-2-microglobulin were pooled and
two final fractions were analyzed by nano-ultra performance
liquid chromatography tandem mass spectrometry (nUPLC-
MS2) on a Fusion Lumos (Thermo Fisher Scientific). Peptides
were separated on a Ultimate 3000 RSLCnano system (Thermo
Fisher Scientific) using a PepMap C18 column, 2µm particle
size, 75µm × 50 cm (Thermo Fisher Scientific) with a 1 h linear
gradient of 3–25% buffer B (0.1% formic acid, 5% DMSO in
acetonitrile) in buffer A (0.1% formic acid, 5% DMSO in water)
at a flow rate of 250 µl/ min. Peptides were introduced using
an Easy-Spray source at 2000V to a Fusion Lumos (Thermo
Fisher Scientific) at 305◦C. Full MS spectra were recorded from
300 to 1,500 m/z in the Orbitrap at 120,000 resolution with
an AGC target of 400,000. Precursor selection was performed
using TopSpeed mode at a cycle time of 2 s. Peptide ions were
isolated using an isolation width of 1.2 amu and trapped at a
maximal injection time of 120ms with an AGC target of 300,000.
Higher-energy collisional dissociation (HCD) fragmentation was
induced at an energy setting of 28 for peptides with a charge
state of 2–4, while singly charged peptides were fragmented
at an energy setting of 32 at lower priority. Fragments were
analyzed in the Orbitrap at 30,000 resolution. Analysis of raw
data was performed using Peaks 7.5 software (Bioinformatics
Solutions). Sequence interpretation of MS2 spectra was carried
out using databases containing all mus musculus UniProt
database entries at a FDR of 1.4. Motif analysis of common
a.a. in peptide sequences was performed using WebLogo 3.5
(weblogo.threeplusone.com). Peptide binding predictions were
performed using NetMHCpan 4.0.
Whole Exome Sequencing
B16F10 melanoma cell line was cultured and collected as
described earlier. DNA was isolated using Purelink genomic
DNA mini kit according to manufacturer’s instructions (Thermo
Fisher Scientific), and gave a yield of 394 ng/ul. The quality of
the DNA yield was assessed by loading an aliquot on 2% agarose
gel. A library was prepared using Agilent SureSelect XT, based
on the cRNA-baits targeted capture. The Mouse All Exon kit
captures 49.6Mb region that covers 221,784 exons within 24,306
genes. Sequencing was performed using HiSeq 2,500 machine
with paired end 2x 25 run, aiming × 100 (raw data) exome
coverage by FASTERIS.
Bioinformatics Analysis of Whole Exome
Sequencing
Sequenced reads from the B16F10 melanoma cell line sample
were mapped to the Mus musculus reference genome assembly
GRCm38 from NCBI using the software BWA-MEM (22) with
default parameters. Supplementary alignments were removed
and the resulting BAM file was sorted with SAMtools (23).
Mapped reads were subsequently used as input for the variant
calling software Platypus (version 0.8.1, specifying the option
“–minFlank=0”) (24) to identify SNPs and short indels (<50
bp). The 74138 identified variants were annotated with standard
R packages using GENCODE and further investigated with
the Variant Effect Predictor Ensembl frame-work (VEP, release
90) (25). Peptides were extracted using a sliding window
from +/−8AA to +/−14AA around the mutation. HLA
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type prediction for H2-Db and H2-Kb alleles was performed
using NetMHC4.0.
In vitro T-Cell Assay
1 × 106 B16F10 melanoma cells were injected into the flank of
C57BL/6 RAG2−/− mice (8–12 weeks old). Twelve days later the
growing tumors were collected and processed for transplantation
into the flank of WT C57BL/6 mice (8–12 weeks old; Harlan)
under anesthesia. The tumors were allowed to grow without any
treatment for 14 days (set as the humane end point 1,000 mm3).
Tumors were collected and digested by DNaseI (Boehringer) and
collagenase D (Roche) in 5% FSC containing DMEM for 1 h at
37◦C. Tumors were then smashed using 100µm cell strainer
(Sigma-Aldrich) and washed 2x with PBS. Tumor-infiltrating
lymphocytes (TILs) were separated using Ficoll-paque premium
(GE Healthcare) by centrifugation for 30min at RT at 1,800 rpm.
TILs were collected and kept on ice. At the same time bone
marrow derived dendritic cells (BMDCs) were prepared from
naïve WT C57BL/6 mice (8–12 weeks old; Harlan). Briefly, bone
marrow cells were cultured in RPMI supplemented with 10%
FCS, glutamine, sodium pyruvate, penicillin, and streptomycin
for 6–8d in the presence of granulocyte-macrophage colony-
stimulating factor containing X-63 cell supernatant. BMDCs
were then pulsed with the selected peptides separately for 1 h
at 37◦C. The pulsed BMDCs were then washed 3x with DMEM
medium and co-cultured with the collected TILs for 6 h at 37◦C
with (1:1,000) Brefeldin A and Monensin (BD Biosciences). ICS
staining was carried out as described in section Intra-cellular
cytokine staining for IFN-γ.
Measuring Treg
Peripheral blood from WT C57BL/6 mice (8–12 weeks old;
Harlan) vaccinated with MTV was collected in heparin. RBCs
were lysed with ACK lysing buffer (Thermo Fisher Scientific)
and cells were stained with anti-CD4 (RM4-5, eBioscience) and
anti-CD25mAb (CD25-4E3, BD Biosciences) for flow cytometric
analysis by FACSCanto and FlowJo Software.
Tumor Experiments and Survival Rate
1 × 106 B16F10 melanoma cells were injected into the flank of
C57BL/6 RAG2−/− mice (8–12 weeks old). Twelve days later the
growing tumors were collected and processed for transplantation
into the flank of WT C57BL/6 mice (8–12 weeks old; Harlan).
Vaccination was carried 5 days later as described in Table 1.
Tumors were collected 14 days later as the control groups
reached the humane end-point of 1,000 mm3. Tumor volume
was measured using a caliper according to the formula V = (W
× W × L)/2, where V is tumor volume, L is tumor length and
W is tumor width. TILs were isolated as described earlier. TILs
were stained with anti-CD8α (53–6.7, BD Biosciences), anti-IFN-
γ (XMG1.2, BD Biosciences), anti-CD45 (30-F11, Biolegend),
anti-Ly6G (1A8, Biolegend), and anti-Ly6C (HK1.4, Biolegend)
for flow cytometric analysis by FACSCanto and FlowJo Software.
Survival was evaluated using the same designated vaccines and
the transplanted WT C57BL/6 mice (8–12 weeks old; Harlan)
were vaccinated twice a week and tumor size was monitored daily
and measured using a caliper.
TABLE 1 | The prepared groups, treatment, and route of injection.
Group Treatment Route of injection
1 120 µg Qβ(CpGs)-VLPs s.c.
2 10 µg anti-CD25 (PC61, Biolegend) i.v.
3 Germline multi-target vaccine (GL-MTV)
120 µg containing:
20 µg Qβ(CpGs)-PMEL17
20 µg Qβ(CpGs)-MTC-1
20 µg Qβ(CpGs)-Calpastatin
20 µg Qβ(CpGs)-ZFP518
20 µg Qβ(CpGs)-TRP-2
20 µg Qβ(CpGs)-Caveolin2
s.c
10 µg anti-CD25 (PC61, Biolegend) i.v.
4 Mutated multi-target
vaccine (Mutated-MTV)
120 µg containing:
60 µg Qβ(CpGs)-Cpsf3l
60 µg Qβ(CpGs)-Kifl8b
s.c.
10 µg anti-CD25 (PC61, Biolegend) i.v.
5 Mix multi-target vaccine (Mix-MTV)
120 µg containing:
15 µg Qβ(CpGs)PMEL17
15 µg Qβ(CpGs) MTC-1
15 µg Qβ(CpGs)-Calpastatin
15 µg Qβ(CpGs)-ZFP518
15 µg Qβ(CpGs)-TRP-2
15 µg Qβ(CpGs)-Caveolin2
15 µg Qβ(CpGs)-Cpsf3l
15 µg Qβ(CpGs)-Kifl8b
s.c.
10 µg anti-CD25 (PC61, Biolegend) i.v.
Statistics
Data have been presented as mean ± SEM using GraphPad
PRISM 7.0d. Comparison between the groups was performed
by Student’s t-test or one-way ANOVA. Tumor growth curves
were analyzed by AUC and survival was analyzed by Log-rank
(Mantel-Cox) test. P-values ∗∗∗∗P < 0.0001; ∗∗∗P < 0.001; ∗∗P <
0.01; ∗P < 0.05.
RESULTS
Algorithm for the Generation of a
Personalized Melanoma Vaccine Platform
Based on VLPs
We adapted the Qβ-VLP/CpG platform for the generation of a
personalized cancer vaccine in mice as illustrated in Figure 1.
Using immunopeptidomics and whole exome sequencing we
identified and predicted tumor-specific germline and mutated
CTL epitopes of the B16F10 melanoma cell line. The identified
and predicted epitopes were then prioritized and validated by
bioinformatics and in vitro experiments.We used bio-orthogonal
copper (Cu)-free click chemistry; a key step in our platform to
couple the selected peptides to CpG-loaded Qβ-VLPs to form
MTV. The vaccines were produced with germline epitopes,
germline-multi target vaccine (GL-MTV) or mutated epitopes
(Mutated-MTV) or a combination of both (Mix-MTV) in mice
transplanted with aggressive B16F10 melanoma tumors.
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FIGURE 1 | Algorithm for the generation of a personalized melanoma vaccine
platform based on VLPs. First, tumor-specific epitopes need to be identified in
a systematic way. Here, immunopeptidomics approach has been used to
identify potential tumor-specific germline epitopes and whole exome
sequencing to predict the mutated ones. In a second step, the identified and
predicted epitopes should be prioritized and this was basically achieved by
bioinformatics and stimulation of tumor-infiltrating cells using in vitro T-cell
assay. Next, the selected epitopes are extended to ∼13–14 amino acids long
peptides using their flanking protein sequence for the goal of targeting CD8+
CTL. The extended peptides are then synthesized and coupled to CpG-loaded
VLPs using Cu-free click chemistry. A mix-multi target VLP-based vaccine is
proposed.
Bio-orthogonal Cu-Free Click Chemistry;
an Efficient Method for Coupling Antigens
to VLPs to Enhance Their Immunogenicity
For the development of VLP-based vaccines, we previously used
SMPH cross-linker to couple the peptide of interest to VLPs
(21, 26–28). Linking of cysteine on peptides to lysine on VLPs
by SMPH has indeed proven reliable for development of VLP-
basedvaccines. However, for the generation of a personalized
cancer vaccine, the method may have several disadvantages,
namely that epitope internal cysteine will also react with SMPH
on VLPs, causing their inactivation and non-reacted SMPH
on VLPs is potentially toxic, requiring complex inactivation,
and purification procedures after coupling. Therefore, this
technique is not well-suited for rapid personalized vaccine
production. For these reasons, we established a coupling
method based on bio-orthogonal Cu-free click chemistry using
a DBCO cross-linker (Figure 2A). This method is non-toxic
and thus enables rapid and efficient coupling of regulatory
compliant GMP produced VLPs and peptides that can potentially
be done at patients’ bedside. We compared the efficiency
of DBCO based Cu-free click chemistry to the standard
SMPH-based method by coupling p33 peptide -as a model
antigen- derived from LCMV to Qβ-VLPs loaded with B-
type CpGs. Cu-free click chemistry significantly enhanced
the coupling of the model antigen to Qβ-VLPs compared
to SMPH when assessed by SDS-PAGE (Figure 2B) and
densitometric analysis demonstrated enhanced peptide coupling
by DBCO compared to SMPH (Figure 2C). In a next step,
we compared the immunogenicity of the vaccines generated
by the two coupling methods in vivo. WT C57BL/6 mice
were vaccinated once subcutaneously (s.c.) with Qβ(CpGs)-p33
vaccine prepared with SMPH or Cu-free click chemistry method.
Qβ-VLPs were packaged with B-type CpGs for successful
activation of DCs and cross-priming. Seven days later, spleens
were collected and tested for p33 specific CD8+ T-cells by
assessing the percentage of p33 tetramer binding and IFN-γ
production. Immunization of C57BL/6 mice with the Qβ(CpGs)-
p33 vaccine based on Cu-free click chemistry resulted in
significant increase in p33 specific CD8+ T-cells (p. 0.0012)
(Figures 2D,G) as well as significant production of IFN-γ (p.
0.0421) (Figure 2E) when compared to SMPH method. Lytic
activity was also enhanced when assayed in vivo by performing
CFSE cytotoxicity assay (Figures 2F,H). Thus, Cu-free click
chemistry improves vaccine immunogenicity compared to the
standard SMPH chemistry.
Identification and Prediction of CD8+
T-Cell Epitopes of B16F10 Melanoma Cells
by Immunopeptidomics and Whole Exome
Sequencing
In a next step, we performed immunopeptidomics for B16F10
murine melanoma cell line to identify peptides naturally
presented on MHC-I molecules. As expected, a large number of
MHC-I-associated peptides was identified (Figures 3A,B). Next,
the peptides were evaluated for a number of essential physical
parameters including the length, MHC haplotype (H2-Db and/or
H2-Kb) and affinity to MHC-I (high affinity ranking peptides)
as summarized in Table 2. Using literature-based assessment
of key characteristics such as being melanocyte-specific or a
candidate oncogene were also considered. Six peptides were
selected from immunopeptidomics for the generation of GL-
MTV includes PMEL17, MTC-1, Calpastatin, ZFP518, TRP-2,
and Caveoline2.
As for mutated peptides, Castle et al. have previously
exploited the mutanome of B16F10 melanoma cell line
and identified several non-synonymous point mutations
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FIGURE 2 | Bio-orthogonal Cu-free click chemistry; an efficient method for coupling antigens to VLPs to enhance their immunogenicity. (A) A sketch illustrating the
coupling method using Bio-orthogonal Cu-free click chemistry (dibenzocyclooctyne NHS ester DBCO). Briefly, NHS ester reacts with Lys residues on VLPs and
incorporates a cyclooctyne moiety which reacts with the azide labeled molecule forming a stable triazole linkage. (B) SDS-PAGE stained with coomassie blue showing
the coupling efficiency of p33 to Qβ(CpGs)-VLP using SMPH cross-linker or DBCO cross-linker. Lane 1 protein marker, lane 2 Qβ-VLP monomer, lane 3
Qβ(CpGs)-VLP derivatized with SMPH cross-linker, lane 4 Qβ(CpGs)-p33 vaccine using SMPH cross-linker, lane 5 Qβ(CpGs)-VLP derivatized with DBCO cross-linker,
lane 6 Qβ(CpGs)-p33 vaccine using DBCO cross-linker. Each extra band in lanes 4 and 6 indicates a peptide binds to a Qβ monomer. (C) Densitometric analysis of
SDS-PAGE lanes 1, 4, and 6. (1) uncoupled Qβ-VLP, total 180 monomers, (2) Qβ(CpGs)-p33 vaccine using SMPH cross-linker, and (3) Qβ(CpGs)-p33 vaccine using
DBCO cross-linker. Notice the percentage of the coupled peptides to Qβ-VLP monomers, total 180 monomers. (D) Percentage of CD8+ Tetramer+ cells (means ±
SEM) in the spleen of vaccinated groups: group 1) Qβ(CpGs)-VLPs, group 2) Qβ(CpGs)-p33 vaccine using SMPH cross-linker, and group 3) Qβ(CpGs)-p33 vaccine
using DBCO cross-linker. (E) Percentage of CD8+ IFN-γ+ secreting cells (means ± SEM) in the spleen of vaccinated groups. (F) CFSE in vivo lytic activity in the
spleen of vaccinated groups, using the formula 100X(1–CFSEHi pulsed/CSFELow un-pulsed). Statistical analysis by Students t-test. (G) Representative FACS plots
showing the percentage of CD8+ Tetramer+ cells in the spleen of vaccinated groups. (H) Representative FACS histogram of CFSE in vivo lytic activity in the spleen of
vaccinated groups. (n = 3) mice per group, one representative of 3 similar experiments is shown. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
and tested >50 peptides in vitro (8). The most promising
peptides with mutations in Kif18b and Cpsf3l genes were
tested separately in vivo for their anti-tumor effect. They
used long synthetic peptides (27 a.a.) targeting both CD8+
and CD4+ cells. Based on these findings we have carried out
whole exome sequencing to confirm somatic point mutations
in these two specific genes in our B16F10 cell line. We
identified several non-synonymous single nucleotide variants
(SNVs), including a point-mutation in the 13th exon of the
Kif18b gene affecting the transcript ENSMUST00000021311
(Chr11:102,908,157; c.2367T>G; p.Lys739Asn) (Figure 3C),
and in the 9th exon of the Cpsf3l gene affecting both
ENSMUST00000120794 (Chr4:155,886,970; c.1021G>A;
p.Asp292Asn) and ENSMUST00000030901 (Chr4:155,886,970;
c.1087G>A; p.Asp314Asn) isoforms (Figure 3D). Accordingly,
mutated Kif18b and Cpsf3l peptides were selected for the
generation of (Mutated-MTV). We have predicted the affinity
of the selected two mutated peptides to H2-Db and H2-Kb
alleles in silico as summarized in Table 3. Please note that we
have only selected the best two mutated peptides from B16F10
melanoma model as the mutation burden in most of other
cancers is low and therefore it is not always feasible to predict
mutated peptides.
In vitro Validation of Germline and Mutated
Epitopes Identified by Immunopeptidomics
and Predicted by Whole Exome
Sequencing
Tumor-infiltrating lymphocytes are highly enriched with tumor
specific T-cells and thus are the most relevant T-cell population
in this regard (29). Therefore, we have used TILs to validate
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FIGURE 3 | Identification and prediction of CD8+ T-cell epitopes of B16F10 melanoma cells by immunopeptidomics and whole exome sequencing. (A) Length
distribution of peptides identified by immunopeptidomics. (B) 8 and 9 mers motifs identified by immunopeptidomics. (C) Whole exome sequencing results showing a
heterozygous SNV (marked in red and orange) in the 13th exon of gene Kif18b at position Chr11:102,908,157 (ENSMUST00000021311: c.2367T>G, p.Lys739Asn),
causing a K>N missense mutation. (D) Whole exome sequencing results showing a heterozygous SNV (marked in orange and green) in the 9th exon of gene Cpsf3l
at position Chr4:155,886,970 (ENSMUST00000120794: c.1021G>A, p.Asp292Asn and ENSMUST00000030901: c.1087G>A; p.Asp314Asn), causing a D>N
missense mutation.
TABLE 2 | The selected peptides from immunopeptidomics for the generation of germline-MTV.
Peptide Sequence # of a.a. MHC haplotype MHC-I affinity
Melanocyte protein PMEL (Melanocyte protein Pmel 17) (Premelanosome
protein) (Silver locus protein) [Cleaved into: M-alpha; M-beta]
VLYRYGSF 8 H2-Kb 0.08
MTC-1 Malignant T- cell-amplified sequence 1 (MCT-1) (Multiple copies T-
cell malignancies 1)
IGIENIHYL 9 H2-Db 0.01
Calpastatin (Calpain inhibitor) SSPANISSL 9 H2-Db, H2-Kb 0.01
Zinc finger protein 518B SSVQNKEYL 9 H2-Kb 0.01
L-dopachrome tautomerase (DCT) (DT) (EC 5.3.3.12) (L-dopachrome
Delta-isomerase) (SLATY locus protein) (Tyrosinase-related protein 2)
(TRP-2) (TRP2)
SQVMNLHNL 9 H2-Kb 0.015
Caveolin2 VMYKFLTV 8 H2-Db, H2-Kb 0.015
the natural immunogenicity of the six selected peptides from
immunopeptidomics and the two mutated epitopes predicted by
whole exome sequencing. The selected peptides were synthesized
for this experiment as 8 or 9 a.a. to study their recognition
by TILs. To this end, TILs were isolated from WT C57BL/6
bearing B16F10 melanoma tumors and cultivated ex vivo with
IL-2 for 2–3 days. The used melanoma cell line has also
been transfected with the model peptide p33 derived from
LCMV which was used as a positive control. The activated
TILs were then co-cultured with BMDCs pulsed separately
with the selected peptides. P33 peptide was used as a positive
internal control while actin peptide was used as a negative
control due to expected strong immune tolerance. IFN-γ
production was then assessed by performing intra-cellular
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cytokine staining (Figures 4A,B). The results indicated that the
selected peptides were effective at inducing significant IFN-γ
production by T-cells when compared to actin. There was no
significant difference between p33 and the selected germline or
mutated peptides.
Multi-Target VLP-Based Vaccine Using
Cu-Free Click Chemistry Could
Significantly Hinder the Progression of the
Aggressive Transplanted B16F10 Tumor
Displaying peptides on CpG-loaded VLPs represents a unique
possibility to increase their immunogenicity for T-cells. Hence,
Qβ-VLPs were used as a scaffold and packaged with B-type CpGs.
The packaging was confirmed by agarose gel and the selected
peptides were coupled to Qβ-VLPs using Cu-free click chemistry.
The vaccines were produced with germline epitopes (GL-MTV)
identified by immunopeptidomics, mutated epitopes (Mutated-
MTV) predicted by whole exome sequencing or a combination of
both (Mix-MTV). The aim of preparing these groups separately
was to compare their overall immunogenicity. The developed
TABLE 3 | The selected peptides from whole-exome sequencing for the
generation of mutated-MTV.
Peptide Sequence # of a.a. MHC
haplotype
MHC-I affinity
Cpsf3l TFADNPGPM 9 H2D
b 0.8855
Kif18b FQEFVDWENV 10 H2D
b 1.7
vaccines were tested in WT C57BL/6 mice bearing the aggressive
B16F10 melanoma tumors. We have adapted a challenging
therapeutic murine melanoma model by transplanting ∼2 mm3
sized B16F10 tumor fragment into the flank ofWTC57BL/6mice
and let it grow for 5 more days in vivo before vaccination started
“Figure 5A.” In order to enhance the efficacy of the developed
MTVs, they were combined with anti-CD25 mAb to deplete
Tregs and facilitate CTLs infiltration. Anti-CD25 was chosen
based on a number of preliminary data showing that anti PD-1
did not enhance the efficacy or immunogenicity of the developed
multi-target VLP-based vaccines against B16F10 melanoma cell
line, while anti-CD25 did (please note that Daclizumab, the
anti-CD25 antibody used in humans, does not deplete Tregs
in vivo). The transplanted WT C57BL/6 mice were vaccinated
s.c. with the developed MTV in combination with low dose of
anti-CD25, 3 times over 14 days as the control groups reached
the ethical end point by day 14 (Figure 5B). The depletion
of Tregs characterized by CD4+, CD25hi was assessed in the
periphery of vaccinatedmice on day 6 post tumor transplantation
(Figures 5C,D). All three multi-target VLP-based vaccines could
significantly hinder the progression of B16F10 melanoma tumor
when assessing the tumor volume at day 14 in comparison
to the groups vaccinated with Qβ(CpGs)-VLP or anti-CD25
alone. However, anti-tumor protection was more efficient when
vaccinating with Mix-MTV than with GL-MTV or Mutated-
MTV (Figures 5E,F). Furthermore, when assessing the growth
curve of the aggressive B16F10 tumors over the 14 days, only
Mix-MTV showed significant reduction in the tumor growth (p
= 0.03). Treatment with anti- Qβ(CpGs)-VLP or CD25 mAb
alone did not show any anti-tumor protection (Figures 5G,H).
FIGURE 4 | Validation of germline and mutated epitopes identified by immunopeptidomics and predicted by whole exome sequencing. (A) Percentage of CD8+
IFN-γ+ secreting cells (means ± SEM) in duplicate, pre-gated on TILs. p33 peptide was used as a positive control and actin as a negative control. Statistical analysis
by Student’s t-test in comparison with Actin (–ve control). (B) Representative FACS plots showing the percentage of CD8+ IFN-γ+ secreting cells pre-gated on TILs
and stimulated with Actin (–ve control), p33 (+ve control), ZFP518, Cpsf3l, PMEL17, and Kif18b peptides. One representative of 3 similar experiments is shown.
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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FIGURE 5 | Multi-target VLP-based vaccine using Cu-free click chemistry could significantly hinder the progression of the aggressive transplanted B16F10 tumor. (A)
A sketch of the challenging therapeutic murine melanoma model based on injecting ∼1 × 106 B16F10 melanoma cell line into the flank of C57BL/6 RAG2−/− mice.
Twelve to thirteen days later the growing tumors are collected and processed for transplantation of ∼2 mm3 into the flank of C57BL/6 WT mice. (B) Vaccination
scheme of five groups: Qβ(CpGs)-VLPs, anti-CD25, germline-multi target vaccine (GL-MTV), Mutated-MTV, and Mix-MTV GL-MTV. (C) Representative percentage of
CD4+ CD25Hi in the periphery of the groups vaccinated with Qβ(CpGs)-VLPs, anti-CD25, and Mix-MTV+anti-CD25 on day 6 post-tumor transplantation. (D)
Representative FACS plots showing the percentage of CD4+ CD25Hi in periphery of the groups vaccinated with Qβ(CpGs)-VLPs, anti-CD25, and
Mix-MTV+anti-CD25 on day 6 post-tumor transplantation. (E) Photographic images of s.c. B16F10 tumors on day 14 post-tumor transplantation. (F) Tumor volume
mm3 (means ± SEM) measured on day 14 post-tumor transplantation for the groups vaccinated with Qβ(CpGs)-VLPs, anti-CD25, GL-MTV, Mutated-MTV and
Mix-MTV, each dot represents a tumor. Statistical analysis by Student’s t-test. (G) Individual tumor growth curves of s.c. B16F10 melanoma of the designated groups.
(H) Combined tumor growth curves of the designated groups, arrows indicate start of treatment. Statistical analysis by AUC. The groups of GL-MTV, Mutated-MTV,
and Mix-MTL were combined with anti-CD25mAb in all experiments. (n = 5) mice per group, one representative of 3 similar experiments is shown.
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Mix Multi-Target VLP-Based Vaccine
Increased CD8+ T-Cell Infiltration Into
B16F10 Tumor and Enhanced the Survival
It is readily accepted that high-grade CD8+ T-cell density in
tumors is correlated with better prognosis and is an essential
piece of evidence for effective immune responses (7, 30). Based
on that, we measured the total number of infiltrating CD8+
T-cells in the tumors and calculated their density in each
vaccinated group (by dividing the total number of CD8+ T-
cells in each tumor by its volume). Mix-MTV significantly
increased CD8+ T-cells density when compared to the groups
vaccinated with Qβ(CpGs)-VLPs (p. 0.0028), anti-CD25 (p.
0.0076), or Mutated-MTV (p. 0.01). The statistical difference
between Mix-MTV and GL-MTV was borderline significant
(p. 0.06) (Figures 6A,C). When assessing the density of CD8+
IFN-γ+ secreting cells in the tumors, the data showed that
Mix-MTV group induced the strongest cytokine production
which was superior to the groups vaccinated with GL-MTV
or Mutated-MTV (Figure 6B). These results underline the
effectiveness of combining both germline and mutated epitopes
in one vaccine when treating the aggressively growing B16F10
melanoma tumor.
Whether the different multi-target VLP-based vaccines can
extend the life-span of tumor-bearing mice was tested next.
Tumors in control mice or mice treated with anti-CD25 mAb
alone reached their ethically allowed maximal size of ∼1,000
mm3 within 13–16 days, underscoring the aggressiveness of
the model used. Vaccination with the GL-MTV or Mutated-
MTV in combination with anti-CD25 mAb extended the
mouse life-span by about 8 days while the Mix-MTV did
so by about 16 days (Figure 6D). In fact, vaccination with
the Mix-MTV reached protective levels of the vaccine based
on p33 peptide, one of the strongest T-cell epitopes known
in mice.
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FIGURE 6 | Mix multi-target VLP-based vaccine increased CD8+ T-cell infiltration into B16F10 tumor and enhanced the survival. (A) Density of CD8+ T-cells (means
± SEM) in tumor, pre-gated on TILs in the groups vaccinated with Qβ(CpGs)-VLPs, anti-CD25, GL-MTV, Mutated-MTV, and Mix-MTV. The density measured by
dividing the total number of CD8+ T-cells in each tumor by its volume. (B) Density of CD8+ IFN-γ+ secreting cells (means ± SEM) in tumor, pre-gated on TILs in the
vaccinated groups. Statistical analysis by one-way ANOVA. (C) Representative FACS plots showing the total number of CD8+ T-cells in each tumor in the vaccinated
groups. (D) Survival of mice in the vaccinated groups, mice were euthanized when the tumor reached 1,000 mm3. The arrows indicate vaccination time. Statistical
analysis by log-rank test. The groups of GL-MTV, Mutated-MTV, and Mix-MTL were combined with anti-CD25mAb in all experiments. (n = 5) mice per group, one
representative of 3 similar experiments is shown. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Mix Multi-Target Vaccine Altered the
Myeloid Composition of B16F10 Tumor
We have studied next the effect of the vaccination with the
prepared multi-target vaccines on tumor myeloid immune cell
composition. Specifically, we have looked at both granulocytic
and monocytic myeloid populations in TILs. There was an
overall increase in the Ly6G+ granulocytic population in the
groups vaccinated with Mix-MTV and GL-MTV in comparison
to the control groups Qβ(CpGs)-VLPs or anti-CD25. However,
the infiltration of Ly6G+ granulocytes into the tumour was
significantly higher in the group vaccinated with Mix-MTV
when compared to the groups vaccinated with GL-MTV
(p. 0.0331) or Mutated-MTV (p. 0.0015) (Figures 7A,C). The
increase in the granulocyte population was accompanied by
a decrease in monocytic population characterized by Ly6C+
which is shown prominently in the group vaccinated with Mix-
MTV (Figures 7B,C). The observed increase in granulocytic
population and the decrease in monocytic one was inversely
correlated with the tumor volume (p 0.0003) as shown in
(Figure 7D) and is compatible with induction of a more
protective environment (31, 32).
DISCUSSION
VLPs have shown to be a promising platform for the development
of effective vaccines. Such platforms significantly enhance
the immunogenicity of tumor epitopes and help overcoming
tolerance and anti-inflammatory milieus (33, 34). Indeed, it has
been shown previously that a VLP-based vaccine can be utilized
for active immunization against melanoma and vaccination
against a single epitope resulted in strong CTL responses
and exerted therapeutic pressure to the extent of provoking
outgrowth of antigen escape variants in mice and humans (17,
18, 35). Personalized cancer vaccines targeting the patient’s tumor
specific mutanome may have the potential to generate clinically
effective T-cell responses (14, 15). In previous studies, multi-
target long peptides, or RNA-based vaccine have been used
to induce CD8+ (and CD4+) T-cell responses in melanoma
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FIGURE 7 | Mix multi-target vaccine altered the myeloid composition of B16F10 tumor. (A) Percentage of Ly6G+ cells (means ± SEM) in TILs, pre-gated on CD45+
cells in the groups vaccinated with Qβ(CpGs)-VLPs, anti-CD25, GL-MTV, Mutated-MTV, and Mix-MTV. (B) Percentage of Ly6C+ cells (means ± SEM) in TILs,
pre-gated on CD45+ cells in the vaccinated groups. Statistical analysis by one-way ANOVA. (C) Representative FACS plots showing the percentage of Ly6G+ and
Ly6C+ cells in TILs in the vaccinated groups. (D) Correlation between the ratio of the percentage of Ly6G+ and Ly6C+ cells over the tumor volume mm3 in the
vaccinated groups. Statistical analysis by linear regression. The groups of GL-MTV, Mutated-MTV, and Mix-MTL were combined with anti-CD25mAb in all
experiments. (n = 5) mice per group, one representative of 3 similar experiments is shown. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
patients. Interestingly, even though the vaccines were designed
to induce CTL responses, they preferentially stimulated CD4+
T-cells, reminiscent of the generally acknowledged difficulties
in mobilizing strong and broad CD8+ T-cell responses by
vaccination (14, 15, 36, 37). Nevertheless, these findings support
the concept that a multi-target vaccine covering a broader range
of cancer antigens can control tumor progression and avoid
outgrowth of antigen-escape variants.
In this study, a novel platform for the generation of
a personalized VLP-based vaccine has been developed by
combining both immunopeptidomics and whole exome
sequencing techniques. Earlier versions of VLP-based vaccines
using SMPH chemistry to couple antigens of interest to VLPs
showed good efficacy. SMPH reacts with free Lysine on the VLP
and free cysteine on the peptides. However, not only cysteines of
the linker but also cysteines within the target epitope may react
with SMPH, resulting in the inactivation of cysteine-containing
epitopes. In addition, non-reacted SMPH on VLPs may be
toxic as it can react with cysteines in the body after injection
of the vaccine. To overcome this problem and enable mixing
and coupling of peptides with VLPs at bedside, a new coupling
chemistry should be employed that leaves cysteines untouched
and that will not react with anything in the host. To this end,
bio-orthogonal Cu-free click chemistry has been implemented
here for GMP-compatible production at bedside. The results
show that DBCO is superior to SMPH cross-linker in terms of
(1) coupling efficiency to Qβ-VLPs and (2) in inducing CTL and
IFN-γ response in-vivo. Bio-orthogonal in general, refers to any
chemical reaction that can occur in the living organism without
causing cellular toxicity or interfering with natural biological
reactions (38). Furthermore, the azide groups attached to the
peptides are metabolically stable and lack any reactivity with
natural biological functionalities in the cells as it only reacts
with the alkyne groups (39, 40). This new coupling method has
shown high selectivity for in vivo studies (41) such as for labeling,
imaging, and tracking cells (39, 42). Cu-free click chemistry
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has been recently applied for the synthesis of glucoconjugate
O-antigen vaccine coupled to CRM197 carrier protein against
Salmonella Typhimurium (43).
Identification of optimal cancer-specific antigens remains a
priority in the field of cancer immunotherapy. Some scientists
favor peptides that are actually presented on the tumor cells
using immunopeptidomics and others rely on epitope prediction
based on whole exome sequencing. The promising clinical trials
conducted so far to test a personalized cancer vaccine have
mainly used whole exome sequencing validated by RNA-seq
to predict tumor-specific neoantigens. Immunopeptidomics
identifies peptides that are actually presented but requires
relatively large amounts of tumor-tissue. By comparison, whole
exome sequencing can be performed with minimal cell numbers,
but epitopes are only predicted and their presence is not actually
physically assessed. In addition, the relative merits of germ-
line vs. mutated epitopes for vaccine design is also disputed.
While the former may be conserved in many patients, the
latter likely induce less or even no immune tolerance, as they
are not expressed in the thymus during early development
nor in the periphery other than in tumor cells (14, 15, 44).
In our study, to directly compare the different approaches,
both immunopeptidomics and whole exome sequencing were
performed to identify and predict both types of T-cell epitopes.
Several T-cell epitopes have been identified and prioritized
by bioinformatics, as well as by their ability to stimulate
TILs from tumor-bearing mice. TILs are highly enriched with
specific T-cells and thus the most relevant T-cell population
for anti-tumor T-cell responses. Using these approaches, two
sets of peptides, germline and mutated epitopes, were identified
and displayed on VLPs loaded with CpGs. In recent years, it
has become evident that anti-tumor response may be enhanced
in the presence of checkpoint inhibitors. Blocking PD-1 vs.
depleting Tregs using anti-CD25 mAb was compared. While
blocking PD-1 had minimal impact on B16F10 tumor growth,
anti-CD25 mAb substantially enhanced protection. Therefore,
the developed multi-target VLP-based vaccines were combined
with anti-CD25 mAb treatment. The results showed that using
germline peptides or mutated or a mixture of both can confer
protection against tumor growth in B16F10 melanoma model.
Interestingly, mixing both types of epitopes was most promising.
This effect was also shown when calculating the density of
CD8+ T-cells or CD8+ IFN-γ+ secreting cells in TILs and
when assessing the effect of the vaccines on the myeloid
composition of the tumor. Indeed, protection using the Mix-
MTV was as potent as observed with the artificial model
antigen, peptide p33, one of the strongest T-cell epitopes known
in mice.
It has been shown previously that eliminating large established
tumors is challenging even in pre-clinical studies. Kelly et al.
has shown that curing a B16F10 melanoma tumor sized 60–80
mm2 is possible when combining four immunotherapeutic
agents (31). Here, we have used a more challenging model
employing transplanted solid tumors rather than single
cell suspension, resulting in tumors with physiological
stroma and vascularization. Combining the multi-target
VLP-based vaccine with anti-CD25 doubled the lifespan
of the transplanted mice and changed the immunological
milieu of the tumors, which is an impressive result given the
model used.
The approach of vaccinating with only two neoantigens and
combining them with germ-line antigens avoids the need for
identifying large numbers of neoantigens that may represent
a particular problem in tumors of low mutational burden. A
prominent example of this is the aggressive metastatic breast
cancer murine cell line 4T1. It has been shown that 4T1
harbored 27 mutations in their expressed genes, however only
one mutation was predicted to bind MHC-I H2-Db allele (45).
These data are consistent with the fact that human tumors
associated with environmental mutagens such as melanoma have
more mutations than other cancers (46). Additionally, Keeping
the numbers of neoantigens lowmay also simplify the production
of this type of personalized vaccines to some extent, as the final
vaccine formulations would vary less from one patient to the next
one, easing the regulatory challenges for producing and releasing
these pharmaceutical products for clinical use.
In conclusion, this study proposes a novel platform for
the development of an immunogenic personalized melanoma
vaccine based on VLPs. This vaccine utilizes CTL epitopes
predicted and validated by both immunopeptidomics and whole
exome sequencing techniques. The peptides were coupled to
the highly immunogenic VLPs by Cu-free click chemistry,
representing a fast, safe and efficient method of coupling,
enabling GMP compliant production for future use in clinical
settings. The platform developed here can be used to target
potentially any malignant tumor and thus can be applied broadly
in cancer medicine.
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